Dr. Anand Gopalsami, MBA, MD

Dr. Gopalsami practices at Cedars-Sinai Medical Center in Los Angeles, California, part of Cedars-Sinai Health System.

Dr. Gopalsami's NPI, 1700224565, was assigned on June 13, 2013. Dr. Gopalsami graduated from Tufts University School Of Medicine in 2013. Dr. Gopalsami's California license number on file is A140824.

Dr. Gopalsami's primary practice is Cedars-Sinai Medical Center, at 8700 Beverly Blvd, Los Angeles, CA 90048 in Los Angeles County. The practice phone is (310) 423-5000.

Dr. Gopalsami's primary practice is Cedars-Sinai Medical Center in Los Angeles, California, part of Cedars-Sinai Health System. The medical group on file is Cedars-Sinai Medical Center.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Gopalsami practices. Vendor and product names are available with a free account.

Emergency medicine is Dr. Gopalsami's primary specialty in the NPI Registry, under taxonomy code 207P00000X. Dr. Gopalsami is board certified in emergency medicine by the American Board of Emergency Medicine. Dmand AI has Dr. Gopalsami's licenses on file in 3 states: California, Indiana and Illinois.

CMS data shows 1,108 Medicare services from Dr. Gopalsami across 6 procedure codes in 2024, for 665 Medicare patients. Medicare paid $83,386 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 665 Medicare patients who saw Dr. Gopalsami in 2024. The largest group is 75 to 84, with 236 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 50% are also on Medicaid. Their average risk score is 3.00, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Gopalsami's median patient age at 53, with 52% women.

In 2024, Dr. Gopalsami wrote 281 Medicare Part D claims for 171 patients. 92% of them were for generic drugs. CMS names the drug for 73 of them, across 6 drugs with 11 or more claims each, at $481 in total drug cost. In 2023, CMS named 78 claims across 6 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 93 out of 100 for Dr. Gopalsami for performance year 2024, reported as part of a group. Dr. Gopalsami accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 3 papers to Dr. Gopalsami, published from 2017 to 2018. The most frequent topics are Emergency Service, Hospital. Dr. Gopalsami's most frequent co-authors are Stephen Tyler Constantine, MD, Ryan Patrick McKillip, MD and Magdeline Araceli Montoya.

CMS Open Payments shows 1 general payment to Dr. Gopalsami from 1 drug or device company in 2016. Food and beverage make up the largest share, 100% of the total. Sanofi and Genzyme US Companies paid the most, $162.

Dr. Gopalsami graduated from Tufts University School Of Medicine in 2013.

Dr. Gopalsami is in network with 1 carrier, including CMS Medicare. Medicare plans come from the most carriers, 1. Check the plan with the practice before a visit.